GlassScriptPhysician profile
Gregory M Kloch
NPI 1285675637
$2,375.34
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $578 · 2021: $478 · 2022: $354 · 2023: $222 · 2024: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $469.28 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $270.56 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $217.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $175.08 | 2020 | |
| Lilly USA, LLC | $170.03 | 2019-2024 | Mounjaro |
| Abbvie INC. | $161.47 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $149.22 | 2020-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Pfizer INC. | $90.79 | 2019-2022 | |
| Astellas Pharma US INC | $76.58 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $76.12 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.38 | 2020-2021 | |
| Glaxosmithkline, LLC. | $69.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.88 | 2020-2023 | Xifaxan |
| Abiomed | $39.18 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $37.76 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $30.41 | 2022-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $29.74 | 2019-2021 | |
| Abbott Laboratories | $24.72 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $23.80 | 2019 | |
| Becton, Dickinson and Company | $21.74 | 2023 | Bd Onclarity |
| Phathom Pharmaceuticals, INC. | $19.49 | 2024 | Voquezna |
| Philips North America LLC | $15.32 | 2024 | (5044) Mcot |
| Exact Sciences Corporation | $13.35 | 2023 | Cologuard Collection Kit |
| Pacira Therapeutics, INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.